Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
The objective of this study is to monitor Health Outcomes of Interest (HOI) in participants
 with human immunodeficiency virus-1 (HIV-1) infection following treatment with Raltegravir.
Study participants contributed data to one or more of 3 cohorts: 1) Historical Cohort:
 HIV-infected participants treated with antiretroviral therapy in the course of ordinary
 clinical practice at the clinics and medical centers of Kaiser Permanente (KP) between 1
 January 2000 and 12 October 2007 (date of market authorization for raltegravir in USA), 2)
 Concurrent Cohort: HIV-infected participant treated with a new non-raltegravir antiretroviral
 therapy in the course of ordinary clinical practice at the clinics and medical centers of KP
 on or after 12 October 2007, and 3) Raltegravir Cohort: HIV-infected participant treated with
 raltegravir in the course of ordinary clinical practice at the clinics and medical centers of
 KP on or after 12 October 2007. Participants could contribute data to more than one cohort,
 but no overlap in follow-up time was allowed.
Inclusion Criteria:

 -  Historical Cohort: HIV-infected participant treated with antiretroviral therapy in the
 course of ordinary clinical practice at the clinics and medical centers of Kaiser
 Permanente (KP) between 1 January 2000 and 12 October 2007 (date of market
 authorization for raltegravir in USA)

 -  Raltegravir Cohort: HIV-infected participant treated with raltegravir in the course of
 ordinary clinical practice at the clinics and medical centers of KP on or after 12
 October 2007

 -  Concurrent Cohort: HIV-infected participant treated with a new non-raltegravir
 antiretroviral therapy in the course of ordinary clinical practice at the clinics and
 medical centers of KP on or after 12 October 2007

 -  All participants must have at least one year of continuous membership with KP prior to
 date when the participant received the first dispensed prescription for study drug
 (index date) to allow for the assessment of medical and treatment history

 Exclusion Criteria:

 -  Less than 18 years of age

 -  Do not receive their medications through the KP pharmacy system

 -  Do not receive their laboratory examinations through the KP system

 -  Participating in the raltegravir phase III or expanded access program